Impact of Membranous Nectin-4 on Outcomes of Platinum-Based Chemotherapy in Metastatic Urothelial Carcinoma
1
Department of Oncology, National Taiwan University Hospital, Taipei 100, Taiwan
2
Department of Pathology, National Taiwan University Hospital, Taipei 100, Taiwan
3
Department of Medical Oncology, National Taiwan University Cancer Center, Taipei 106, Taiwan
4
Department of Urology, National Taiwan University Hospital, Taipei 100, Taiwan
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(3), 433; https://doi.org/10.3390/cancers17030433
Submission received: 9 January 2025
/
Revised: 24 January 2025
/
Accepted: 26 January 2025
/
Published: 27 January 2025
(This article belongs to the Special Issue Clinical Outcomes in Urologic Cancers)
Simple Summary
Metastatic urothelial carcinoma (mUC) is commonly treated with platinum-based chemotherapy (Plt-ChT) as the first-line regimen, but patient responses vary significantly, and predictive biomarkers are lacking. Nectin-4, a cell adhesion molecule and the target of the antibody–drug conjugate enfortumab vedotin, holds potential as a biomarker but has not been thoroughly investigated in the context of chemotherapy. This study evaluated whether membranous nectin-4 expression (mNectin-4) could predict the efficacy of Plt-ChT, including gemcitabine plus cisplatin or carboplatin, in mUC. Analyzing tumor samples from 96 patients revealed that higher mNectin-4 expression was associated with a non-significant trend towards improved outcomes, particularly with gemcitabine and cisplatin therapy. These findings suggest that mNectin-4 may serve as a potential predictive biomarker for refining treatment selection and personalizing therapeutic strategies for mUC. Further validation through larger prospective studies is required to confirm its clinical utility.
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
Metastatic urothelial carcinoma (mUC) is a highly aggressive malignancy [...]
